Rising Consumer Class
Tap into companies strategically positioned to capture the growing purchasing power of emerging market consumers. These carefully selected stocks represent businesses that professional analysts believe will benefit from rising disposable incomes in developing economies worldwide.
Top Picks from This Group
Here are a few of the assets in this group. Create an account to unlock the full list.
Alibaba Group
BABA
Current price
$119.99
A multinational technology company specializing in e-commerce, retail, and internet services, with a massive footprint in China and other Asian market...
A multinational technology company specializing in e-commerce, retail, and internet services, with a massive footprint in China and other Asian markets.
Join Nemo FREE today and unlock every stock.
It only takes 60 seconds.
About This Group of Stocks
Our Expert Thinking
This collection focuses on the massive economic shift happening as millions join the middle class in developing nations. As disposable incomes rise in these regions, consumer spending accelerates, creating substantial growth opportunities for companies that can capture this new demand.
What You Need to Know
These companies span multiple sectors—from e-commerce and digital payments to luxury goods and food services. They all share significant exposure to high-growth regions in Asia, Africa, and Latin America, with digital infrastructure expansion serving as a key catalyst for their growth.
Why These Stocks
Each company was selected for its strong market position, established brand power, and direct revenue exposure to emerging economies. These businesses are already capturing the rising consumer wave and are strategically positioned to benefit from long-term demographic and economic trends.
12 Month Growth Potential
Use the growth calculator to see how much investing in these assets could return over one year.
If you invested across these assets:
in 12 months it could be worth:
+14.04%
Group Performance Snapshot
Average 12 Month Profit
On average, analysts expect assets in this group to grow 14.04% over the next year.
Stocks Rated Buy by Analysts
13 of 13 assets in this group are rated Buy by professional analysts.
Group Growth
This group averaged a 1% return last month.
Why You'll Want to Watch These Stocks
Tapping Into 3 Billion New Consumers
These companies have front-row access to the world's fastest-growing consumer markets. As billions move into the middle class across Asia, Africa, and Latin America, their spending power creates massive opportunities.
Digital Revolution Meets Rising Incomes
The combination of smartphone adoption and increasing disposable income is creating a perfect storm of growth. These companies are positioned at the intersection of these powerful trends.
Where Your Money Could Grow Next
While developed markets mature, these companies are capturing fresh growth in regions where consumer spending is just beginning to take off. This could represent the next wave of potential long-term returns.
Why Invest with Nemo Money?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
The New Cost of Compliance: Investing in HR Tech
Australian airline Qantas received a historic $58 million fine for unlawfully dismissing workers, setting a new precedent for corporate accountability in labor practices. This ruling creates an investment opportunity in companies that provide the essential HR, legal, and compliance technologies businesses now need to navigate stricter labor law enforcement.
GLP-1s Target Liver Disease
The FDA's approval of Wegovy for a serious liver disease has boosted Novo Nordisk's market position and highlighted a major new application for GLP-1 drugs. This development creates an investment opportunity in companies focused on innovative treatments for metabolic and liver-related conditions.
Pharma's Digital Prescription
Novo Nordisk is partnering with GoodRx to offer its popular drug Ozempic at a reduced price, boosting GoodRx's stock. This collaboration highlights a growing trend of pharmaceutical companies leveraging digital health platforms to improve drug affordability and expand market reach.
Frequently Asked Questions
Everything you need to know about the product and billing.